This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16. The primary hypothesis is Vericiguat is superior to placebo in reducing NT-proBNP at Week 16.
Conditions
- Heart Failure
- Left Ventricular Systolic Dysfunction
Intervention
- Vericiguat tablet
- Vericiguat suspension
- Placebo tablet
- Placebo suspension
Principal Investigator
- Shwaish, Natalie
Sponsor
- Merck Sharp & Dohme
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.